|
Oncogenes and Tumor Suppressors
Citations 211-220 of 795 total displayed.
|
Past content
(since May 2000):
|
Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies
- Karen Stephens, Molly Weaver, Kathleen A. Leppig, Kyoko Maruyama, Peter D. Emanuel, Michelle M. Le Beau, and Kevin M. Shannon
Blood 2006; 108: 1684-1689.
[Abstract]
[Full text]
[PDF]
Multiple myeloma cell survival relies on high activity of protein kinase CK2
- Francesco A. Piazza, Maria Ruzzene, Carmela Gurrieri, Barbara Montini, Luca Bonanni, Gino Chioetto, Giovanni Di Maira, Francesca Barbon, Anna Cabrelle, Renato Zambello, Fausto Adami, Livio Trentin, Lorenzo A. Pinna, and Gianpietro Semenzato
Blood 2006; 108: 1698-1707.
[Abstract]
[Full text]
[PDF]
Oncogenic K-ras cooperates with PML-RAR to induce an acute promyelocytic leukemia-like disease
- Iris T. Chan, Jeffery L. Kutok, Ifor R. Williams, Sarah Cohen, Sandra Moore, Hirokazu Shigematsu, Timothy J. Ley, Koichi Akashi, Michelle M. Le Beau, and D. Gary Gilliland
Blood 2006; 108: 1708-1715.
[Abstract]
[Full text]
[PDF]
A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation
- Lynn McCallum, Susan Price, Nathalie Planque, Bernard Perbal, Andrew Pierce, Anthony D. Whetton, and Alexandra E. Irvine
Blood 2006; 108: 1716-1723.
[Abstract]
[Full text]
[PDF]
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia
- Stephen Breit, Martin Stanulla, Thomas Flohr, Martin Schrappe, Wolf-Dieter Ludwig, Gabriele Tolle, Margit Happich, Martina U. Muckenthaler, and Andreas E. Kulozik
Blood 2006; 108: 1151-1157.
[Abstract]
[Full text]
[PDF]
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
- Nikolas von Bubnoff, Paul W. Manley, Jurgen Mestan, Jana Sanger, Christian Peschel, and Justus Duyster
Blood 2006; 108: 1328-1333.
[Abstract]
[Full text]
[PDF]
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD
- Jennifer L. Rocnik, Rachel Okabe, Jin-Chen Yu, Benjamin H. Lee, Neill Giese, David P. Schenkein, and D. Gary Gilliland
Blood 2006; 108: 1339-1345.
[Abstract]
[Full text]
[PDF]
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBP
- Giovanna Ferrari-Amorotti, Karen Keeshan, Michela Zattoni, Clara Guerzoni, Giorgio Iotti, Sara Cattelani, Nick J. Donato, and Bruno Calabretta
Blood 2006; 108: 1353-1362.
[Abstract]
[Full text]
[PDF]
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate
- Niove E. Jordanides, Heather G. Jorgensen, Tessa L. Holyoake, and Joanne C. Mountford
Blood 2006; 108: 1370-1373.
[Abstract]
[Full text]
[PDF]
Sorafenib is a potent inhibitor of FIP1L1-PDGFR and the imatinib-resistant FIP1L1-PDGFR T674I mutant
- Els Lierman, Cedric Folens, Elizabeth H. Stover, Nicole Mentens, Helen Van Miegroet, Werner Scheers, Marc Boogaerts, Peter Vandenberghe, Peter Marynen, and Jan Cools
Blood 2006; 108: 1374-1376.
[Abstract]
[Full text]
[PDF]
|
|
